Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States.
The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels.
It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 27, 25 | -0.58 Increased by +15.94% | -0.67 Increased by +13.50% |
| Nov 5, 24 | -0.59 Increased by +18.06% | -0.69 Increased by +14.21% |
| Aug 8, 24 | -0.59 Increased by +32.18% | -0.66 Increased by +10.84% |
| May 8, 24 | -0.59 Increased by +29.76% | -0.71 Increased by +16.90% |
| Feb 27, 24 | -0.69 Decreased by -2.99% | -0.82 Increased by +15.85% |
| Nov 7, 23 | -0.72 Increased by +8.86% | -0.92 Increased by +21.74% |
| Aug 10, 23 | -0.87 Decreased by -3.57% | -0.92 Increased by +5.43% |
| May 15, 23 | -0.84 Decreased by -35.48% | -0.78 Decreased by -7.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 13.08 M Increased by +154.28% | -50.03 M Decreased by -3.48% | Decreased by -382.53% Increased by +59.30% |
| Sep 30, 24 | 6.87 M Increased by +120.24% | -50.13 M Decreased by -9.56% | Decreased by -730.27% Increased by +50.25% |
| Jun 30, 24 | 6.69 M Increased by +219.73% | -49.80 M Increased by +7.74% | Decreased by -744.25% Increased by +71.14% |
| Mar 31, 24 | 5.70 M Increased by +305.63% | -48.74 M Decreased by -6.66% | Decreased by -855.77% Increased by +73.70% |
| Dec 31, 23 | 5.14 M Increased by +408.30% | -48.35 M Decreased by -17.69% | Decreased by -939.97% Increased by +76.85% |
| Sep 30, 23 | 3.12 M Increased by +235.52% | -45.76 M Increased by +1.64% | Decreased by -1.47 K% Increased by +70.68% |
| Jun 30, 23 | 2.09 M Increased by +N/A% | -53.98 M Decreased by -35.98% | Decreased by -2.58 K% Decreased by N/A% |
| Mar 31, 23 | 1.40 M Increased by +N/A% | -45.69 M Decreased by -60.84% | Decreased by -3.25 K% Decreased by N/A% |